Global Blood-Based Biomarkers Market Size, By Type (Genetic Biomarkers), By Application (Cancer, Cardiovascular, Neurological Diseases), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction), By End Use, and Regional Forecasts 2022-2032

Description

The global blood-based biomarkers market is valued at approximately USD 7.32 billion in 2023 and is anticipated to grow at a CAGR of 7.2% over the forecast period 2024-2032. The market is experiencing significant growth due to the rising prevalence of chronic and degenerative diseases, including cancer, cardiovascular diseases, and neurological disorders. The ability of blood-based biomarkers to offer non-invasive, cost-effective, and early disease detection solutions has positioned them as a preferred diagnostic tool in modern precision medicine.

The increasing adoption of next-generation sequencing (NGS), polymerase chain reaction (PCR), and liquid biopsy technologies has enhanced the accuracy and efficiency of biomarker-based diagnostics. Liquid biopsy-based biomarker testing is revolutionizing oncology by enabling early cancer detection through circulating tumor DNA (ctDNA) analysis. Moreover, advancements in AI-driven biomarker analysis are optimizing disease prediction models and personalized treatment plans, improving patient outcomes. Strategic industry partnerships, such as the collaboration between ADx NeuroSciences and Alamar Biosciences for high-sensitivity neurodegenerative biomarkers, further fuel market expansion.

Despite its strong growth trajectory, regulatory and reimbursement challenges present hurdles in widespread biomarker adoption. Limited reimbursement frameworks in healthcare systems, particularly for emerging biomarker-driven diagnostics, can impact accessibility and affordability. However, continued government investments in precision medicine, rising awareness of preventive diagnostics, and improving regulatory pathways for biomarker approval are expected to mitigate these barriers over time.

North America holds the largest market share, attributed to strong R&D investments, an established healthcare infrastructure, and increasing adoption of biomarker-based diagnostics. The U.S. market, in particular, is witnessing a surge in approvals for innovative biomarker-based tests, such as Labcorp's pTau217 blood biomarker for Alzheimer's disease. The Asia Pacific region is projected to experience the fastest growth, driven by expanding healthcare access, rising chronic disease prevalence, and growing biomarker research investments in China, India, and Japan.

Major Market Players Included in This Report:

Abbott
F. Hoffmann-La Roche Ltd.
Siemens Healthineers AG
Thermo Fisher Scientific, Inc.
Bio-Rad Laboratories, Inc.
Cleveland Diagnostics, Inc.
BIOMERIEUX
Sysmex Corporation
Exact Sciences Corporation
Quanterix Corporation
Guardant Health, Inc.
Menarini Silicon Biosystems
Sunbird Bio
QIAGEN N.V.
Harbinger Health

The Detailed Segments and Sub-Segments of the Market are Explained Below:

By Type:

Genetic Biomarkers
Protein Biomarkers
Metabolic Biomarkers
Cell-Based Biomarkers
Epigenetic Biomarkers

By Application:

Cancer
Cardiovascular Diseases
Neurological Diseases
Immunological Diseases
Others

By Technology:

Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Immunoassays
Mass Spectrometry
Others

By End Use:

Hospitals & Clinics
Diagnostic Laboratories
Research & Academic Institutes
Others

By Region:

North America:

U.S.
Canada
Mexico

Europe:

UK
Germany
France
Italy
Spain
Sweden
Denmark
Norway

Asia Pacific:

China
Japan
India
South Korea
Australia
Thailand

Latin America:

Brazil
Argentina

Middle East & Africa:

Saudi Arabia
UAE
South Africa
Kuwait

Years Considered for the Study Are as Follows:

Historical Year - 2022, 2023
Base Year - 2023
Forecast Period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years (2022-2032)
Annualized Revenue and Regional Level Analysis for Each Market Segment
Detailed Geographical Landscape Analysis with Country-Level Market Insights
Competitive Landscape, Market Share Analysis & Key Business Strategies
Demand-Supply Analysis & Future Market Outlook
Key Investment Opportunities & Emerging Trends in the Facial Tissues Industry
Regulatory Landscape & Impact on Market Growth

Chapter 1. Global Blood-Based Biomarkers Market Executive Summary

1.1. Global Blood-Based Biomarkers Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Type
- 1.3.2. By Application
- 1.3.3. By Technology
- 1.3.4. By End Use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Blood-Based Biomarkers Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Blood-Based Biomarkers Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising incidence of cancer, cardiovascular, and neurological diseases
- 3.1.2. Growing adoption of liquid biopsy and non-invasive diagnostics
- 3.1.3. Technological advancements in biomarker-based detection methods
3.2. Market Challenges
- 3.2.1. Limited reimbursement policies for biomarker-driven diagnostics
- 3.2.2. Stringent regulatory requirements affecting approval timelines
3.3. Market Opportunities
- 3.3.1. Increasing R&D investments in precision medicine and personalized healthcare
- 3.3.2. Expanding role of AI and machine learning in biomarker discovery
- 3.3.3. Growth in strategic collaborations and industry partnerships

Chapter 4. Global Blood-Based Biomarkers Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Blood-Based Biomarkers Market Size & Forecasts by Type (2022-2032)

5.1. Segment Dashboard
5.2. Global Blood-Based Biomarkers Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Genetic Biomarkers
- 5.2.2. Protein Biomarkers
- 5.2.3. Metabolic Biomarkers
- 5.2.4. Cell-Based Biomarkers
- 5.2.5. Epigenetic Biomarkers

Chapter 6. Global Blood-Based Biomarkers Market Size & Forecasts by Application (2022-2032)

6.1. Segment Dashboard
6.2. Global Blood-Based Biomarkers Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Cancer
- 6.2.2. Cardiovascular Diseases
- 6.2.3. Neurological Diseases
- 6.2.4. Immunological Diseases
- 6.2.5. Others

Chapter 7. Global Blood-Based Biomarkers Market Size & Forecasts by Technology (2022-2032)

7.1. Segment Dashboard
7.2. Global Blood-Based Biomarkers Market: Technology Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Next-Generation Sequencing
- 7.2.2. Polymerase Chain Reaction
- 7.2.3. Immunoassays
- 7.2.4. Mass Spectrometry
- 7.2.5. Others

Chapter 8. Global Blood-Based Biomarkers Market Size & Forecasts by End Use (2022-2032)

8.1. Segment Dashboard
8.2. Global Blood-Based Biomarkers Market: End-Use Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Hospitals & Clinics
- 8.2.2. Diagnostic Laboratories
- 8.2.3. Research & Academic Institutes
- 8.2.4. Others

Chapter 9. Global Blood-Based Biomarkers Market Size & Forecasts by Region (2022-2032)

9.1. North America
- U.S.
- Canada
- Mexico
9.2. Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
9.3. Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
9.4. Latin America
- Brazil
- Argentina
9.5. Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Kuwait

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
- 10.1.1. Abbott
- 10.1.2. F. Hoffmann-La Roche Ltd.
- 10.1.3. Thermo Fisher Scientific, Inc.
10.2. Top Market Strategies
10.3. Company Profiles
- Siemens Healthineers AG
- Bio-Rad Laboratories, Inc.
- Cleveland Diagnostics, Inc.
- BIOMERIEUX
- Sysmex Corporation
- Exact Sciences Corporation
- Quanterix Corporation
- Guardant Health, Inc.
- Menarini Silicon Biosystems
- Sunbird Bio
- QIAGEN N.V.
- Harbinger Health

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes